文献速递产科母胎医学

阿司匹林、出生体重与大于胎龄儿:ASPRE 试验的二次分析

Aspirin, Birthweight, and Large-For-Gestational-Age Neonates: A Secondary Analysis of the ASPRE Trial.
PubMed 文献 · BJOG · 2025-07-01

该研究为 ASPRE 试验的二次分析,纳入 1571 例单胎活产儿(阿司匹林组 777 例,安慰剂组 794 例),比较两组出生体重分布及大于胎龄儿(LGA)发生率。阿司匹林与出生体重从<2500 g 向 2500-4000 g 及出生体重百分位从<25th 向 25th-75th 百分位偏移相关,LGA 发生率无显著增加(5.5% vs 6.2%,p=0.667)。在孕前糖尿病女性中,阿司匹林可能与更高的 LGA 发生率相关,需进一步研究。

要点

  • 阿司匹林与出生体重向 2500-4000 g 及 25th-75th 百分位偏移相关。
  • LGA 发生率阿司匹林组 5.5% vs 安慰剂组 6.2%,无显著差异(p=0.667)。
  • 孕前糖尿病与治疗存在显著交互作用(p=0.034)。

核心结论

  • 阿司匹林使用与出生体重增加相关,但不增加 LGA 发生率;在孕前糖尿病女性中,阿司匹林可能与更高的 LGA 发生率相关,需进一步研究。

研究设计与样本

  • ASPRE 试验的二次分析,纳入早产子痫前期高风险且活产的参与者,比较试验组间出生体重分布及 LGA 发生率。
  • 共纳入 1571 例单胎活产儿,其中阿司匹林组 777 例,安慰剂组 794 例。
  • 分析按孕前糖尿病及子痫前期发生情况分层,并使用逻辑回归探究 LGA(出生体重>90th 百分位)的独立预测因素。

主要发现

  • 阿司匹林与出生体重从<2500 g 向 2500-4000 g 偏移相关,出生体重百分位从<25th 向 25th-75th 偏移相关。
  • LGA 发生率阿司匹林组 5.5% vs 安慰剂组 6.2%,无显著差异(p=0.667)。
  • 逻辑回归显示治疗与孕前糖尿病存在显著交互作用(p=0.034)。
  • 母亲体重与 LGA 呈正相关(校正 OR 1.040,95%CI 1.030-1.051,p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effects of aspirin on the distribution of birthweight and its impact on the rates of large-for-gestational-age (LGA) neonates. DESIGN: Secondary analysis of the Combined Multimarker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Preeclampsia Prevention (ASPRE) trial. SETTING: Thirteen hospitals in England, Spain, Belgium, Greece, Italy and Israel. POPULATION: Participants of the ASPRE trial at increased risk of preterm pre-eclampsia (PE) who had a live birth. METHODS: We compared the birthweight distributions and the rates of LGA neonates between the trial groups. Analyses were stratified according to the presence of pre-existing diabetes mellitus and the development of PE, and logistic regression was used to investigate independent predictors of LGA neonates with birthweight above the 90th percentile. MAIN OUTCOME MEASURES: Birthweight distribution and rates of LGA neonates. RESULTS: Among 1571 singleton, live neonates (777 from the aspirin group and 794 from the placebo group), aspirin was associated with a shift in birthweight from < 2500 to 2500-4000 g, and birthweight percentile from < 25th to 25th-75th percentiles, with no significant increase in LGA neonates (5.5% vs. 6.2%, p = 0.667). Logistic regression demonstrated a significant interaction between treatment and pre-existing diabetes (p-value 0.034), and a positive association between maternal weight and LGA neonates (adjusted odds ratio 1.040, 95% confidence interval 1.030-1.051, p < 0.001). CONCLUSIONS: Aspirin use is associated with increased birthweight without increasing the rate of LGA neonates. Among women with pre-existing diabetes, aspirin may be associated with a higher rate of LGA neonates, warranting further investigation.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Rolnik DL, Poon LC, Syngelaki A, et al. Aspirin, Birthweight, and Large-For-Gestational-Age Neonates: A Secondary Analysis of the ASPRE Trial. BJOG. 2025. PMID: 40590060. doi:10.1111/1471-0528.18263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。